CODX
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company\'s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Co-Diagnostics, Inc. Common Stock (CODX) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | A (4.2) | C (2.5) | C (2.4) | C- (1.9) | C+ (2.7) |
| 2026-08-04 | C+ (2.7) | A (4.2) | C (2.5) | C (2.4) | C- (1.9) | C+ (2.8) |
| 2026-08-03 | C+ (2.7) | B- (3.0) | C+ (2.8) | C (2.4) | C- (2.0) | C+ (2.6) |
| 2026-08-02 | C+ (2.7) | B- (3.0) | C+ (2.7) | C (2.4) | C- (1.9) | C+ (2.6) |
| 2026-07-29 | C+ (2.6) | F (0.0) | B (3.2) | D+ (1.8) | D+ (1.5) | D+ (1.8) |